Skip to main content
ORNL scientists developed a method that improves the accuracy of the CRISPR Cas9 gene editing tool used to modify microbes for renewable fuels and chemicals production. This research draws on the lab’s expertise in quantum biology, artificial intelligence and synthetic biology. Credit: Philip Gray/ORNL, U.S. Dept. of Energy

Scientists at ORNL used their expertise in quantum biology, artificial intelligence and bioengineering to improve how CRISPR Cas9 genome editing tools work on organisms like microbes that can be modified to produce renewable fuels and chemicals.

ORNL’s Fernanda Santos examines a soil sample at an NGEE Arctic field site in the Alaskan tundra in June 2022. Credit: Amy Breen, University of Alaska Fairbanks.

Wildfires are an ancient force shaping the environment, but they have grown in frequency, range and intensity in response to a changing climate. At ORNL, scientists are working on several fronts to better understand and predict these events and what they mean for the carbon cycle and biodiversity.

TIP graphic

Scientist-inventors from ORNL will present seven new technologies during the Technology Innovation Showcase on Friday, July 14, from 8 a.m.–4 p.m. at the Joint Institute for Computational Sciences on ORNL’s campus.

Oak Ridge National Laboratory led a team of scientists to design a molecule that disrupts the infection mechanism of the SARS-CoV-2 coronavirus and could be used to develop new treatments for COVID-19 and future virus outbreaks. Credit: Michelle Lehman/ORNL, U.S. Dept. of Energy

A team of scientists led by the Department of Energy’s Oak Ridge National Laboratory designed a molecule that disrupts the infection mechanism of the SARS-CoV-2 coronavirus and could be used to develop new treatments for COVID-19 and other viral diseases.

Computational systems biologists at ORNL worked with the U.S. Department of Veterans Affairs and other institutions to identify 139 locations across the human genome tied to risk factors for varicose veins, marking a first step in the development of new treatments. Credit: Andy Sproles/ORNL, U.S. Dept. of Energy

As part of a multi-institutional research project, scientists at ORNL leveraged their computational systems biology expertise and the largest, most diverse set of health data to date to explore the genetic basis of varicose veins.

A pure lipid membrane formed using lipid-coated water droplets exhibits long-term potentiation, or LTP, associated with learning and memory, emulating hippocampal LTP observed in the brains of mammals and birds. Credit: Jill Hemman/ORNL, U.S. Dept. of Energy

While studying how bio-inspired materials might inform the design of next-generation computers, scientists at ORNL achieved a first-of-its-kind result that could have big implications for both edge computing and human health.

Technology Innovation Program

Five technologies invented by scientists at the Department of Energy’s Oak Ridge National Laboratory have been selected for targeted investment through ORNL’s Technology Innovation Program.

MDF Exterior

ORNL scientists will present new technologies available for licensing during the annual Technology Innovation Showcase. The event is 9 a.m. to 3 p.m. Thursday, June 16, at the Manufacturing Demonstration Facility at ORNL’s Hardin Valley campus.

An artist's rendering of the Ultium Cells battery cell production facility to be built in Spring Hill, Tennessee, which will employ 1,300 people. Recognizing the unique expertise of their organizations, ORNL, TVA, and the Tennessee Department of Economic and Community Development have been working together for several years to bring startups developing battery technologies for EVs and established automotive firms to Tennessee. Credit: Ultium Cells

ORNL, TVA and TNECD were recognized by the Federal Laboratory Consortium for their impactful partnership that resulted in a record $2.3 billion investment by Ultium Cells, a General Motors and LG Energy Solution joint venture, to build a battery cell manufacturing plant in Spring Hill, Tennessee.

Neutron scattering experiments show electric charges, shown in red, blue and grey, in the SARS-CoV-2 main protease site where telaprevir binds to the structure. The experiments provide critical data for the design of small-molecule drugs to treat COVID-19. Credit: Jill Hemman and Michelle Lehman/ORNL, U.S. Dept. of Energy

Scientists have found new, unexpected behaviors when SARS-CoV-2 – the virus that causes COVID-19 – encounters drugs known as inhibitors, which bind to certain components of the virus and block its ability to reproduce.